RESUMO
BACKGROUND: In addition to factors intrinsic to bipolar disorder (BD), sexual functioning (SF) can be affected by extrinsic causes, such as psychotropic drugs. However, the effect of mood stabilizers on SF and quality of life (QoL) is an underexplored research area. AIM: To analyze SF in BD outpatients in euthymia for at least 6 months treated only with mood stabilizers and the association between SF and QoL. METHODS: A multicenter cross-sectional study was conducted in 114 BD outpatients treated with (i) lithium alone (L group); (ii) anticonvulsants alone (valproate or lamotrigine; A group); (iii) lithium plus anticonvulsants (L+A group); or (iv) lithium plus benzodiazepines (L+B group). The Changes in Sexual Functioning Questionnaire Short Form (CSFQ-14) was used. Statistical analyses were performed to compare CSFQ-14 scores among the pharmacological groups. An adaptive lasso was used to identify potential confounding variables, and linear regression models were used to study the association of the CSFQ-14 with QoL. MAIN OUTCOME MEASURES: Self-reports on phases of the sexual response cycle (ie, desire, arousal, and orgasm) and QoL were assessed. RESULTS: The A group had better total SF scores than the L group and the L+B group. Relative to the A group, the L and L+B groups had worse sexual desire; the L group had worse sexual arousal; and the L+A group and the L+B group had worse sexual orgasm. Regarding sociodemographic factors, being female and older age were associated with worse total SF and all subscale scores. Among all subscales scores, higher sexual arousal scores were associated with better QoL. CLINICAL IMPLICATIONS: Potential modified extrinsic factors such as psychotropic medication that can affect SF can be addressed and adjusted to lessen side effects on SF. STRENGTHS & LIMITATIONS: Sample of patients with euthymic BD in treatment with mood stabilizers and no antipsychotics or antidepressants, substance use as an exclusion criterion, and use of a validated, gender-specific scale to evaluate SF. Major limitations were cross-sectional design, sample size, and lack of information about stability of relationship with partner. CONCLUSIONS: Lithium in monotherapy or in combination with benzodiazepines is related to worse total SF and worse sexual desire than anticonvulsants in monotherapy. While the addition of benzodiazepines or anticonvulsants to lithium negatively affects sexual orgasm, sexual arousal (which plays a significant role in QoL) improves when benzodiazepines are added to lithium. Anticonvulsants in monotherapy have the least negative effects on SF in patients with BD. García-Blanco A, García-Portilla MP, Fuente-Tomás L de la, et al. Sexual Dysfunction and Mood Stabilizers in Long-Term Stable Patients With Bipolar Disorder. J Sex Med 2020;17:930-940.
Assuntos
Antipsicóticos , Transtorno Bipolar , Idoso , Anticonvulsivantes/uso terapêutico , Antimaníacos/uso terapêutico , Antipsicóticos/uso terapêutico , Transtorno Bipolar/tratamento farmacológico , Estudos Transversais , Feminino , Humanos , Qualidade de VidaRESUMO
Editorial of vol. 32-2.
Editorial del vol. 32-2.
Assuntos
Consumo de Bebidas Alcoólicas , Betacoronavirus , Infecções por Coronavirus , Pandemias , Pneumonia Viral , Uso de Tabaco , COVID-19 , Humanos , SARS-CoV-2RESUMO
Sexual functioning in bipolar disorder (BD) is dependent on multiple clinical and demographic determinants that can eventually lead to sexual dysfunction. However, the contribution of affective temperaments remains unstudied in this population. In this cross-sectional multicentric work, we studied the impact of temperament traits on sexual functioning in 100 euthymic BD outpatients treated only with mood stabilizers with or without benzodiazepines. Temperament was evaluated using the Temperament Evaluation of Memphis, Pisa, Paris, and San Diego - Autoquestionnaire (TEMPS-A) and sexual functioning with the Changes on Sexual Functioning Questionnaire (CSFQ-14). The effect of temperament on sexual functioning was analyzed using Bayesian ordinal regression models, which included age, gender, BD type, dominant polarity, metabolic syndrome, marital status, and affective symptomatology. Our results showed that hyperthymic traits predicted a significantly higher CSFQ-14 score for global sexual functioning (OR = 1.222; 95% CI [1.073, 1.431]), desire (OR = 1.164; 95% CI [1.025, 1.357]), arousal (OR = 1.278; 95% CI: [1.083, 1.551]), and orgasm (OR = 1.182; 95% CI [1.037, 1.365]). We did not find a significant contribution for other types of temperaments. Better sexual functioning was also associated with a better quality of life. Our findings highlight the importance of temperament traits in sexual functioning in euthymic BD, which may have implications in sexual dysfunction prevention.
Assuntos
Transtorno Bipolar , Temperamento , Teorema de Bayes , Transtorno Bipolar/complicações , Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/psicologia , Estudos Transversais , Humanos , Inventário de Personalidade , Qualidade de Vida , Inquéritos e QuestionáriosRESUMO
There is a scarcity of studies assessing the influence of biomarkers in metabolic syndrome in psychiatric patients. Our aim was to correlate serum or plasma levels of 25-hydroxyvitamin D (25-OH-VD), retinol, vitamin B12 (VB12), folate and homocysteine (Hcy), with the metabolic status, in a sample of 289 outpatients with Schizophrenia or Bipolar Disorder. Logistic regression and multiple linear regressions were performed to assess the ability of biomarkers to predict the presence of MetS, the number of risk factors for MetS, and insulin resistance indexes (HOMA and QUICKI). Regarding the association between biomarkers and the QUICKI index, the model explained 6.8% of the variance, with folate and 25-OH-VD levels contributing significantly to the model. The model predicting the number of MetS risk factors was significant and explained 21.7% of the variance, being 25-OH-VD and retinol the statistically significant factors. As for the impact of biomarkers on MetS, the model was statistically significant, being 25-OH-VD and retinol levels the significant factors. We report for the first time an association between MetS and both low 25-OH-VD and high retinol concentrations. Inflammation-related biomarkers may help identify patients with a high risk of MetS who might benefit from healthy lifestyle counselling and early intervention.
Assuntos
Carbono/metabolismo , Transtornos Mentais/sangue , Síndrome Metabólica/sangue , Vitamina A/sangue , Vitamina D/análogos & derivados , Adulto , Biomarcadores/sangue , Estudos Transversais , Feminino , Humanos , Resistência à Insulina/fisiologia , Masculino , Transtornos Mentais/diagnóstico , Transtornos Mentais/psicologia , Síndrome Metabólica/diagnóstico , Síndrome Metabólica/psicologia , Pessoa de Meia-Idade , Fatores de Risco , Vitamina D/sangue , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/diagnóstico , Deficiência de Vitamina D/psicologiaRESUMO
INTRODUCTION: Bipolar disorder (BD) is a heterogeneous disorder needing personalized and shared decisions. We aimed to empirically develop a cluster-based classification that allocates patients according to their severity for helping clinicians in these processes. METHODS: Naturalistic, cross-sectional, multicenter study. We included 224 subjects with BD (DSM-IV-TR) under outpatient treatment from 4 sites in Spain. We obtained information on socio-demography, clinical course, psychopathology, cognition, functioning, vital signs, anthropometry and lab analysis. Statistical analysis: k-means clustering, comparisons of between-group variables, and expert criteria. RESULTS AND DISCUSSION: We obtained 12 profilers from 5 life domains that classified patients in five clusters. The profilers were: Number of hospitalizations and of suicide attempts, comorbid personality disorder, body mass index, metabolic syndrome, the number of comorbid physical illnesses, cognitive functioning, being permanently disabled due to BD, global and leisure time functioning, and patients' perception of their functioning and mental health. We obtained preliminary evidence on the construct validity of the classification: (1) all the profilers behaved correctly, significantly increasing in severity as the severity of the clusters increased, and (2) more severe clusters needed more complex pharmacological treatment. CONCLUSIONS: We propose a new, easy-to-use, cluster-based severity classification for BD that may help clinicians in the processes of personalized medicine and shared decision-making.
Assuntos
Transtorno Bipolar/classificação , Adulto , Transtorno Bipolar/diagnóstico , Transtorno Bipolar/psicologia , Análise por Conglomerados , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medicina de Precisão , Psicometria , Reprodutibilidade dos Testes , Índice de Gravidade de Doença , EspanhaRESUMO
Introducción. El impacto psicológico en las etapas iniciales de la pandemia por COVID-19 y el confinamiento fue mayor en personas con trastornos mentales. En este estudio se exploraron las diferencias en el impacto psicológico según el sexo en personas con trastorno de ansiedad en España. Metodología. Estudio transversal, descriptivo y comparativo de los datos aportados por los participantes en una encuesta online anónima realizada entre el 19 y el 26 de marzo de 2020. El cuestionario ad hoc incluyó datos sociodemográficos, clínicos y variables relacionadas con COVID-19,junto con preguntas sobre estrategias de afrontamiento y las versiones en español de la Escala de Escalas de Depresión Ansiedad Estrés (DASS-21) y la Escala de Impacto del Estresor(IES). Se utilizaron análisis descriptivos bivariados y modelos de regresión logística. Resultados. De los 21.207 participantes, se analizaron1617 (7,6%) personas con trastorno de ansiedad autoinformado [1347 (83,3%) mujeres; 270 (16,7%) varones]. El impacto psicológico fue mayor en las mujeres que en los hombres con diferencias estadísticamente significativas en cada subescala del DASS-21 y subescalas del IES. Después de ajustar por posibles variables de confusión, se observó que ser mujer se asoció con puntuaciones más altas en las subescalas de pensamientos intrusivos y evitativos. Conclusiones. Nuestro estudio sugiere que las mujeres con trastorno de ansiedad son un grupo vulnerable a un mayor impacto negativo en la salud mental y, especialmente, en los síntomas relacionados con el trastorno de estrés postraumático. (AU)
Background. The early psychological impact of the COVID-19 pandemic and lockdown is greater in peoplewith mental disorders. This study explored the differences in the psychological impact on people with an anxiety disorder by sex in Spain. Methods. Cross-sectional, descriptive, comparative study of the data provided by participants in an anonymous online survey between March 19 and 26, 2020. Thead hoc questionnaire included sociodemographic, clinical,and variable data related to COVID-19, along with questions about coping strategies, and the Spanish versions ofthe Depression, Anxiety, and Stress Scale (DASS-21) andImpact of Event Scale (IES). Descriptive bivariate analyses and logistic regression models were used. Results. Of the 21,207 participants, 1617 (7.6%) people with self-reported anxiety disorder were analyzed [1347(83.3%) females; 270 (16.7%) males]. The psychological impact was greater on women than men with statistically significant differences in each subscale of the DASS-21and subscales of the IES. After adjusting for potential confounding variables, it was observed that being awoman was associated with higher scores on the intrusiveand avoidant thoughts subscales. Conclusions. Our study suggests that women with ananxiety disorder are a group vulnerable to a greater negative impact on mental health and, especially, symptomsr elated to post-traumatic stress disorder. (AU)
Assuntos
Humanos , Masculino , Feminino , Impacto Psicossocial , Pandemias , Infecções por Coronavirus/epidemiologia , Transtornos de Ansiedade/psicologia , Distribuição por Sexo , Espanha , Estudos Transversais , Epidemiologia Descritiva , PsicologiaRESUMO
Introduction: Apathy is a negative symptom of schizophrenia and is associated with poor real world functioning. Therefore, it is important to have validated psychometric instruments to assess this symptom. This is the first study to validate the Spanish adaptation of the self-rated version of the Apathy Assessment Scale (AES-S) in patients with schizophrenia.Materials and methods: Naturalistic, cross-sectional, validation study in 104 patients with schizophrenia evaluated using the following scales: Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP), Clinical Assessment Interview for Negative Symptoms (CAINS), Self-report of Negative Symptoms (SNS), Motivation and Pleasure Scale-Self-Report (MAP-SR), Calgary Depression Scale for Schizophrenia (CDSS), and Apathy Evaluation Scale-self-rated version (AES-S).Results: Reliability: Internal consistency (Cronbach's alpha) was 0.908. Convergent validity: The Pearson correlation coefficient between AES-S and CAINS-MAP total scores was −0.483 (p<0.001). For SNS, total and avolition subscale scores were −0.803 and −0.639 (p<0.001), respectively. With the MAP-SR, the correlation coefficient was −0.727 (p<0.001). Divergent validity: The Pearson correlation coefficient between AES-S and PSP total scores was 0.504 (p<0.001). Furthermore, with the CDSS, the correlation coefficient was −0.431 (p<0.001). Discriminant validity: The AES-S discriminated between different levels of illness severity according to CGI-S scores. Factor analysis: A three-component solution explained 57.32% of the variance. Pearson correlations between coefficients were 12=0.265, 13=0.464, and 23=0.060. (AU)
Introducción: La apatía es un síntoma negativo de la esquizofrenia, y está asociada a un mal funcionamiento del mundo real. Por tanto, es importante disponer de instrumentos psicométricos validados para valorar este síntoma. Este es el primer estudio que valida la adaptación al español de la versión auto-evaluada de la escala de evaluación de la apatía (AES-S) en pacientes esquizofrénicos.Material y métodos: Estudio naturalista, transversal y de validación realizado en 104 pacientes esquizofrénicos evaluados utilizando las escalas siguientes: Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP), Clinical Assessment Interview for Negative Symptoms (CAINS), Self-report of Negative Symptoms (SNS), Motivation and Pleasure Scale-Self-Report (MAP-SR), Calgary Depression Scale for Schizophrenia (CDSS) y Apathy Evaluation Scale-self-rated version (AES-S).Resultados: Fiabilidad: La consistencia interna (alfa de Cronbach) fue de 0,908. Validez convergente: El coeficiente de correlación de Pearson entre las puntuaciones totales de AES-S y CAINS-MAP fue de −0,483 (p<0,001). Para SNS, las puntaciones totales y de la subescala de abulia fueron de −0,803 y −0,639 (p<0,001), respectivamente. En cuanto a la escala MAP-SR, el coeficiente de correlación fue de −0,727 (p<0,001). Validez divergente: El coeficiente de correlación de Pearson entre las puntuaciones totales de AES-S y PSP fue de 0,504 (p<0,001). Además, en la escala CDSS, el coeficiente de correlación fue de −0,431 (p<0,001). Validez discriminante: La escala AES-S discriminó entre los diferentes niveles de gravedad de la enfermedad, conforme a las puntuaciones CGI-S. Análisis factorial: Una solución de tres componentes explicó el 57,32% de la varianza. Las correlaciones de Pearson entre los coeficientes fueron de 1-2=0,265, 1-3=0,464 y 2-3=0,060. (AU)
Assuntos
Humanos , Esquizofrenia , ApatiaRESUMO
Introduction:Negative symptoms can be grouped into five domains: apathy/avolition, anhedonia, asociality, alogia, and affective flattening. There are few validate self-rated measures that assess these five dimensions. Therefore, this study aimed to validate the Self-Evaluation of Negative Symptoms (SNS) in Spanish patients with schizophrenia.Material and methods:Cross-sectional, validation study in 104 outpatients with schizophrenia evaluated using the Spanish version of the following scales: Clinical Assessment Interview for Negative Symptoms (CAINS), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale for Schizophrenia (CGI-SCH), Personal and Social Performance (PSP), Motivation and Pleasure Scale Self-Report (MAP-SR), 36-item Short-Form Health Survey (SF-36) and the Self-Evaluation of Negative Symptoms (SNS).Results Reliability:Internal consistency (Cronbach's alpha) was 0.915. Convergent validity: The Pearson correlation coefficient between MAP-SR and SNS Total scores was 0.660 (p<0.001). For PANSS-N, the correlation was 0.437 (p<0.005) and with the CAINS-Total was 0.478 (p<0.005). Divergent validity: The Pearson correlation coefficient between SNS and PSP was r=−0.372 (p≤0.001), and with SF-36 Physical and Mental Summary Component scores were r=−0.213 (p=0.066) and r=−0.144 (p=0.219), respectively. Discriminant validity: SNS Total scores were significantly statistically different according to the severity of the negative symptomatology rated by the CGI-SCH negative scale (p<0.001). (AU)
Introducción:Los síntomas negativos pueden agruparse en 5 dominios: apatía/abulia, anhedonia, conductas asociales, afasia y aplanamiento afectivo. Existen pocas medidas validadas autocalificadas que evalúen estas 5 dimensiones. Por tanto, el objetivo de este estudio fue validar la herramienta Self-Evaluation of Negative Symptoms (SNS, Autoevaluación de síntomas negativos) en pacientes españoles esquizofrénicos.Material y métodos:Estudio transversal de validación en 104 pacientes esquizofrénicos externos, evaluados utilizando la versión española de las escalas siguientes: Clinical Assessment Interview for Negative Symptoms (CAINS), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale for Schizophrenia (CGI-SCH), Personal and Social Performance (PSP), Motivation and Pleasure Scale-Self-Report (MAP-SR), 36-item Short-Form Health Survey (SF-36) y la SNS.Resultados: Respecto a la fiabilidad,la consistencia interna (α de Cronbach) fue de 0,915. En cuanto a validez convergente, el coeficiente de correlación de Pearson entre las puntuaciones totales de MAP-SR y SNS fue de 0,660 (p < 0,001). Para PANSS-N, la correlación fue de 0,437 (p < 0,005) y de 0,478 (p < 0,005) con CAINS-Total. Respecto a la validez divergente, el coeficiente de correlación de Pearson entre las puntuaciones SNS y PSP fue de r = 0,372 (p ≤ 0,001) y con las puntuaciones de SF-36 Physical and Mental Summary Component fueron de r = −0,213 (p = 0,066) y r = −0,144 (p = 0,219), respectivamente. En la validez discriminante, las puntuaciones totales de SNS fueron diferentes desde un punto de vista estadístico significativo, conforme a la gravedad de la sintomatología negativa calificada por la escala negativa CGI-SCH (p < 0,001). (AU)
Assuntos
Humanos , Esquizofrenia , Sintomas Psíquicos , Afasia , ApatiaRESUMO
Introducción: Hay evidencias que sugieren la existencia de alteraciones de algunas citocinas en pacientes con esquizofrenia, pero su asociación con la psicopatología aún no está clara. El objetivo de este estudio es determinar si los niveles de citocinas proinflamatorias (factor de necrosis tumoral-alfa, interleucina [IL]-6, IL-2, IL-1ß, IL-1RA) están aumentados en pacientes ambulatorios clínicamente estables en comparación con individuos sanos, y analizar si podrían ser biomarcadores específicos de las diferentes dimensiones clínicas de la esquizofrenia. Métodos: Se evaluaron 73 pacientes con esquizofrenia en sus primeros 10 años de evolución de la enfermedad y 73 controles sanos pareados por edad y sexo. Se realizó una evaluación precisa de las dimensiones clínicas (positiva, negativa, depresiva y cognitiva) en estos pacientes. Resultados: Solo los niveles de IL-6 están significativamente elevados en los pacientes tras controlar por índice de masa corporal, perímetro abdominal, tabaquismo y tratamiento psicofarmacológico en comparación con sus controles sanos. Tras ajustar por varios factores de confusión, los modelos de regresión lineal múltiple identificaron cómo las concentraciones de IL-1ß predicen los síntomas negativos, psicopatología general y gravedad global de la Escala del Síndrome Positivo y Negativo, mientras los niveles de IL-2 predicen el dominio motivación y placer de la Entrevista de Evaluación Clínica para Síntomas Negativos y la puntuación global en la Escala de Funcionamiento Personal y Social. Sin embargo, el rendimiento cognitivo, la gravedad de los síntomas depresivos y positivos no correlacionaron con ninguna de las citocinas. Conclusiones: Nuestros hallazgos sugieren que las concentraciones de IL-6 permanecen elevadas en pacientes estables con esquizofrenia. Mientras que la IL-2 marca específicamente la gravedad en el dominio motivación y placer de la sintomatología negativa, la IL-1ß no es específica para esta dimensión, ya que también predice la gravedad de la sintomatología general y global
Introduction: Evidence suggests the existence of cytokine disturbances in patients with schizophrenia but their association with psychopathology is still unclear. The aim of the current study was to determine if pro-inflammatory cytokine levels (tumor necrosis factor-alfa, interleukin (IL)-6, IL-2, IL-1ß, IL-1RA) are increased in stable outpatients compared with healthy subjects, and to analyze if they could be specific biomarkers of clinical dimensions in schizophrenia. Methods: We studied 73 stable outpatients with schizophrenia in their first 10 years of illness and 73 age- and sex-matched healthy controls. An accurate assessment of clinical dimensions (positive, negative, depressive, cognitive) was performed in patients. Results: Only IL-6 levels were significantly increased in patients after controlling for body mass index, waist circumference, smoking, and psychopharmacological treatment, compared with healthy subjects. After adjusting for several confounders, multiple linear regression models identified that Positive and Negative Syndrome Scale negative symptoms, general psychopathology, and global severity are predicted by IL-1ß concentrations, while motivation and pleasure domain of Clinical Assessment Interview for Negative Symptoms and Personal and Social Performance global functioning scores are predicted by IL-2 levels. Cognitive performance, positive, and depressive symptom severity did not correlate with any cytokine. Conclusions: Our findings suggested that IL-6 concentrations are elevated in stable patients with schizophrenia. Whereas IL-2 specifically marks severity of the motivation and pleasure domain of negative symptoms, IL-1ß is not specific to this dimension as it also predicts severity of general and global symptomatology
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Esquizofrenia/fisiopatologia , Interleucina-2/análise , Interleucina-1beta/análise , Transtornos Psicóticos/fisiopatologia , Disfunção Cognitiva/diagnóstico , Biomarcadores/análise , Citocinas/análise , Estudos de Casos e Controles , Interleucina-6/análise , Avaliação de Sintomas/métodos , Índice de Gravidade de Doença , Manejo de Espécimes/métodos , Tabagismo/epidemiologiaRESUMO
La estadificación clínica es una herramienta diagnóstica utilizada en otras especialidades de la medicina que surge de la combinación de un enfoque categorial y dimensional. En las últimas 2 décadas, se ha planteado su aplicación en el campo de la psiquiatría, fundamentalmente como herramienta de ayuda diagnóstica, de orientación terapéutica y pronóstica. En este trabajo se revisan los modelos de estadificación clínica que han sido propuestos hasta la fecha para el trastorno bipolar, la depresión y la esquizofrenia. Se realizó una búsqueda bibliográfica en las bases de datos PubMed y Medline. Se seleccionaron con base en los criterios de inclusión y exclusión un total de 15 estudios. Se describen y comparan las características de cada uno de los modelos agrupados según el tipo de trastorno para el que fueron propuestos (trastorno bipolar: 4; depresión: 5; esquizofrenia: 6). Como conclusión, identificamos la necesidad de validar empíricamente dichos modelos para así demostrar que son una herramienta útil en la práctica clínica habitual
Clinical staging is a diagnostic tool used in other medical specialties, which has resulted from the combination of a categorical and dimensional approach. In the last 2 decades, the usefulness of its application in the field of psychiatry has been suggested, mainly as a tool for diagnostic help, and therapeutic and prognostic orientation. In this paper we review the clinical staging models that have been proposed to date for bipolar disorder, depression and schizophrenia. A literature search was performed in PubMed and Medline databases. A total of 15 studies were selected according to inclusion and exclusion criteria. Models were grouped according to the type of disorder for which staging was proposed (bipolar disorder: 4, depression: 5, schizophrenia: 6), and their characteristics were described. As a conclusion, we identify the need to empirically validate these models to demonstrate that staging is a useful tool for clinical practice
Assuntos
Humanos , Transtornos Mentais/classificação , Transtorno Bipolar/classificação , Transtorno Depressivo/classificação , Esquizofrenia/classificação , Transtornos Bipolares e Relacionados/diagnóstico , Índice de Gravidade de Doença , Progressão da DoençaRESUMO
No disponible
Assuntos
Humanos , Suicídio/psicologia , Tentativa de Suicídio/psicologia , Testes Neuropsicológicos/estatística & dados numéricos , Emoções Manifestas , Fatores de Risco , Biomarcadores , Medicina de Precisão/tendênciasRESUMO
Recientemente se ha planteado que las alteraciones de las capas de la retina podrían ser un biomarcador de determinados trastornos mentales, al derivar esta de la misma capa embrionaria que el cerebro y estar conectada con este a través del nervio óptico. El objeto del presente artículo es ofrecer una revisión sistemática de la literatura y una síntesis temática sobre el estado actual de las alteraciones de las capas de la retina identificadas mediante tomografía de coherencia óptica en los pacientes con esquizofrenia, trastorno bipolar y depresión mayor. Para ello se realizó una búsqueda sistemática de la literatura, la lectura crítica de los artículos seleccionados y la síntesis temática de los resultados. Los pacientes con esquizofrenia son los que presentan más alteraciones, seguidos de los pacientes con trastorno bipolar, siendo muy escasos los hallazgos en la depresión. La capa de fibras nerviosas de la retina es la capa retiniana con más alteraciones en la esquizofrenia y en el trastorno bipolar, mientras que ningún estudio en depresión mayor encontró alteraciones en ella. De los parámetros clínicos, la duración de la enfermedad correlaciona significativa e inversamente con el grosor de las distintas capas en todos los trastornos. A la hora de interpretar estos datos es necesario tener en cuenta las limitaciones y diferencias de los estudios, especialmente el tiempo medio de evolución de los trastornos. Dado que este era muy diferente entre los 3 trastornos (más del doble en el caso de la esquizofrenia respecto a la depresión mayor), las diferencias en los resultados encontrados podrían deberse más al efecto del tiempo de evolución que al trastorno en sí. En conclusión, los hallazgos de la tomografía de coherencia óptica son esperanzadores, ya que podrían proporcionar biomarcadores de la neurodegeneración y/o neuroprogresión tanto de la esquizofrenia como del trastorno bipolar
It has recently been suggested that alterations of the layers of the retina could be a biomarker of specific mental disorders since they originate in the same embryonic layer as the brain and both are interconnected through the optic nerve. The purpose of this article is to offer a systematic review of the literature and a thematic synthesis on the current state of the alterations of the retina layers identified by optical coherence tomography in patients with schizophrenia, bipolar disorder and major depression. For this purpose, we performed a bibliographic search, a systematic review of the studies and a thematic synthesis of the reported findings. Patients with schizophrenia have more abnormal findings followed by patients with bipolar disorder, with very few findings in depression. The nerve fiber layer is the retinal layer with more abnormal findings both in schizophrenia and in bipolar disorder, while no study in major depression found alterations in it. Of the clinical parameters, the duration of the illness correlates significantly and inversely with the thickness of the different layers in all disorders. When interpreting these data, it is necessary to take into account the limitations and differences of the studies, especially the mean length of the disorders. Given that this was very different among the 3 disorders (more than doubled in the case of schizophrenia respect to major depression), the differences in the results found could be due more to the effect of the length of illness than to the disorder itself. In summary, optical coherence tomography findings are promising, since they could provide biomarkers of neurodegeneration and/or neuroprogression of both schizophrenia and bipolar disorder
Assuntos
Humanos , Retina/ultraestrutura , Distrofias Retinianas/complicações , Transtornos Mentais/fisiopatologia , Transtorno Depressivo Maior/diagnóstico , Transtorno Bipolar/diagnóstico , Esquizofrenia/diagnóstico , Distrofias Retinianas/diagnóstico por imagem , Biomarcadores/análise , Tomografia de Coerência Óptica/métodosRESUMO
Smoking and depression are related in a bidirectional way: smoking is the primary avoidable cause of illness and death in patients with depression, and depression is one of the most consistent risk factors for smoking. The main objective of this study is to investigate the relationship between smoking and depression, analyzing sociodemographic and clinical variables such as severity of symptoms, subtype of affective disorder, and its impact on suicidal behavior in the clinical population. A sample of 201 patients, over 18 years of age [mean age (SD) = 53.76 (10.36) years; women = 132 (65.7%)], with a history of depressive episode (unipolar or bipolar) or dysthymia (ICD 10 criteria) was studied. Current smoking prevalence was 43.2% and life-time prevalence 61.2%. No statistically significant differences in smoking prevalence between men and women were found (X2 = 3.896, p = 0.143). The average age of onset was 17.81 (5.60) years. There was a tendency towards a linear association between number of cigarettes/day consumed and severity of depression according to the Hamilton Depression Scale (HDRS) in current smokers (Pearsons R = 0.298, p = 0.050). Multinomial logistic regression analysis showed that current tobacco consumption was associated with higher HDRS scores, with each additional point on the HDRS increasing the likelihood of smoking by 0.062 [p = 0.032; OR (95% CI) = 1.064 (1.005-1.125)].Our results showed that depressed patients present higher prevalence of current smoking than the general population, also suggesting a relationship between severity of consumption and severity of depressive symptoms
Tabaquismo y depresión se relacionan de forma bidireccional: el tabaquismo es la primera causa evitable de enfermedad y muerte en pacientes con depresión, y la depresión constituye uno de los factores de riesgo de tabaquismo más consistentes. El principal objetivo del presente trabajo es profundizar en la relación entre tabaquismo y depresión, analizando variables socio-demográficas y clínicas como la gravedad de los síntomas, el subtipo de trastorno afectivo, y su impacto en las conductas suicidas en población clínica. Se estudió una muestra de 201 pacientes, mayores de 18 años [edad media (SD) = 53,76 (10,36) años; mujeres = 132 (65,7%)], con historia de episodio depresivo (unipolar o bipolar) o distimia (criterios CIE 10). La prevalencia de tabaquismo actual fue 43,2% y la prevalencia vida 61,2%, no existiendo diferencias estadísticamente significativas entre hombres y mujeres (X2 = 3,896; p = 0,143). La edad media de inicio fue 17,81 (5,60) años. Se observó tendencia a asociación lineal entre número de cigarrillos/día consumidos y gravedad de la depresión según la Escala de Hamilton para la Depresión (HDRS) en los consumidores actuales de tabaco (R de Pearson = 0,298; p = 0,050). El análisis de regresión logística multinomial puso de manifiesto que el consumo actual de tabaco se asocia con puntuaciones más elevadas en la HDRS, de modo que cada incremento de un punto en dicha escala, la posibilidad de fumar aumenta en 0,062 [p = 0,032; OR (95% CI) = 1,064 (1,005-1,125)]. Nuestros resultados muestran que los pacientes deprimidos presentan mayor prevalencia de consumo actual de tabaco que la población general, sugiriendo además una relación entre gravedad de consumo y gravedad de los síntomas de depresión
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Transtorno Depressivo/epidemiologia , Transtorno Depressivo/psicologia , Fumar/efeitos adversos , Comorbidade , Estudos Transversais , Transtorno Depressivo/complicações , Prevalência , Fatores de Risco , Índice de Gravidade de Doença , Fumar/epidemiologia , Fatores Socioeconômicos , Ideação Suicida , Uso de Tabaco/epidemiologia , Uso de Tabaco/psicologia , Tabagismo/psicologiaRESUMO
Introducción: Diversos estudios han encontrado un aumento de los parámetros de estrés oxidativo en pacientes con esquizofrenia. Los objetivos de este estudio han sido identificar potenciales biomarcadores de estrés oxidativo en pacientes con esquizofrenia estables, durante los primeros 10 años de enfermedad, y determinar si se asocian con dimensiones clínicas específicas. Material y métodos: Se evaluaron 73 pacientes clínicamente estables y 73 controles sanos pareados por edad y sexo. Se recogieron datos sociodemográficos, clínicos y parámetros biológicos. Los biomarcadores sanguíneos incluyeron homocisteína, porcentaje de hemólisis, subproductos de peroxidación lipídica y, como biomarcador antioxidante, actividad de la catalasa en eritrocitos. Resultados: Los análisis comparativos tras controlar por tabaquismo y síndrome metabólico evidenciaron un aumento significativo en la actividad de la catalasa en pacientes. Asimismo, niveles inferiores de peroxidación lipídica se asociaron de manera significativa con la sintomatología negativa. Conclusiones: Como conclusión, los mecanismos compensatorios antioxidantes podrían estar aumentados en pacientes con esquizofrenia estables durante las fases iniciales. Además, podría existir una relación inversa entre el estrés oxidativo y la dimensión negativa
Introduction: Several studies have described increased oxidative stress parameters in patients with schizophrenia. The objectives of the current study were to identify potential oxidative stress biomarkers in stable patients during first 10 years of schizophrenia and determine if they are associated with specific clinical dimensions. Material and methods: Seventy-three clinically stable outpatients with schizophrenia and 73 sex and age-matched healthy controls were recruited. Sociodemographic, clinical and biological data were collected at enrollment. Blood biomarkers included homocysteine, the percentage of hemolysis, lipid peroxidation subproducts, and as an antioxidant biomarker, catalase activity in erythrocytes. Results: Comparative analyses after controlling for smoking and metabolic syndrome evidenced a significant increase in catalase activity in patients. Also, lower lipid peroxidation levels showed an association with negative symptoms. Conclusions: In conclusion, compensatory antioxidant mechanisms might be increased in stable patients with schizophrenia at early stages. Furthermore, there may be an inverse relationship between oxidative stress and negative dimension
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Esquizofrenia/fisiopatologia , Estresse Oxidativo/fisiologia , Peroxidação de Lipídeos/fisiologia , Catalase/análise , Biomarcadores/análise , Estudos de Casos e Controles , Tabagismo/epidemiologia , Síndrome Metabólica/epidemiologia , Antioxidantes/fisiologia , Mediadores da Inflamação/análise , Inflamação/fisiopatologia , Estudos LongitudinaisRESUMO
La sintomatología de la esquizofrenia es heterogénea, no existiendo ningún síntoma patognomónico de la misma. Además, su diagnóstico presenta dificultades, ya que se basa en información subjetiva en lugar de en marcadores. El propósito de este estudio es ofrecer una revisión del estado actual de los biomarcadores sanguíneos de las dimensiones psicopatológicas de la esquizofrenia. En pacientes con esquizofrenia se han observado disfunciones inflamatorias, hormonales o metabólicas y se ha intentado establecer los biomarcadores responsables de esas disfunciones. La identificación de estos podría contribuir al diagnóstico y tratamiento de la esquizofrenia (AU)
Symptomatology of schizophrenia is heterogeneous, there is not any pathognomonic symptom. Moreover, the diagnosis is difficult, since it is based on subjective information, instead of markers. The purpose of this study is to provide a review of the current status of blood-based biomarkers of psychopathological dimensions of schizophrenia. Inflammatory, hormonal or metabolic dysfunctions have been identified in patients with schizophrenia and it has attempted to establish biomarkers responsible for these dysfunctions. The identification of these biomarkers could contribute to the diagnosis and treatment of schizophrenia (AU)